X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-20 | ACLX | Arcellx, Inc. | Lubner David Charles | Dir | S - Sale+OE | $75.00 | -6,000 | 21,659 | -22% | -$450,000 | |||||
| M | 2026-01-15 | SRZN | Surrozen, Inc./De | Column Group III Gp, LP | 10% | P - Purchase | $19.74 | +32,507 | 2,261,777 | +1% | +$641,597 | |||||
| M | 2026-01-15 | SRZN | Surrozen, Inc./De | Kutzkey Tim | Dir, 10% | P - Purchase | $19.74 | +32,507 | 2,261,777 | +1% | +$641,597 | |||||
| D | 2026-01-16 | NBIX | Neurocrine Biosciences Inc | Gano Kyle | CEO | S - Sale+OE | $132.71 | -36,400 | 140,407 | -21% | -$4,830,458 | |||||
2026-01-20 | AURA | Aura Biosciences, Inc. | Elazzouzi Amy | SVP, Finance | S - Sale | $4.86 | -1,581 | 84,081 | -2% | -$7,684 | ||||||
2026-01-20 | AURA | Aura Biosciences, Inc. | De Los Pinos Elisabet | See Remarks | S - Sale | $4.86 | -16,928 | 585,226 | -3% | -$82,270 | ||||||
| D | 2026-01-20 | KYMR | Kymera Therapeutics, Inc. | Esposito Pamela | Dir | S - Sale+OE | $67.91 | -5,500 | 0 | -100% | -$373,521 | |||||
2026-01-15 | BEAM | Beam Therapeutics Inc. | Bellon Christine | GC | S - Sale | $34.61 | -18,629 | 97,038 | -16% | -$644,832 | ||||||
2026-01-14 | APGE | Apogee Therapeutics, Inc. | Henderson Michael Thomas | CEO | S - Sale | $81.11 | -20,000 | 1,192,987 | -2% | -$1,622,159 | ||||||
| D | 2026-01-14 | SRRK | Scholar Rock Holding Corp | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | S - Sale+OE | $45.20 | -13,112 | 108,964 | -11% | -$592,611 | |||||
2026-01-15 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $124.31 | -3,000 | 150,503 | -2% | -$372,930 | ||||||
2026-01-15 | GILD | Gilead Sciences, Inc. | Mercier Johanna | Chief Commercial Officer | S - Sale | $124.31 | -3,000 | 103,221 | -3% | -$372,930 | ||||||
2026-01-16 | CCCC | C4 Therapeutics, Inc. | Reyno Leonard | Chief Medical Officer | S - Sale | $2.22 | -10,000 | 156,382 | -6% | -$22,200 | ||||||
2026-01-13 | SRRK | Scholar Rock Holding Corp | Sinha Vikas | CFO | S - Sale | $42.70 | -16,755 | 583,245 | -3% | -$715,439 | ||||||
2026-01-13 | SRRK | Scholar Rock Holding Corp | Woods Keith | COO | S - Sale | $42.70 | -16,746 | 583,254 | -3% | -$715,054 | ||||||
2026-01-13 | SRRK | Scholar Rock Holding Corp | Vaishnaw Akshay | Pres of R, D | S - Sale | $42.70 | -20,438 | 595,767 | -3% | -$872,703 | ||||||
2026-01-13 | SRRK | Scholar Rock Holding Corp | Hallal David | CEO | S - Sale | $42.70 | -57,450 | 1,746,645 | -3% | -$2,453,115 | ||||||
2026-01-13 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $40.00 | -3,000 | 137,031 | -2% | -$120,000 | ||||||
| D | 2026-01-13 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale+OE | $40.00 | -23,279 | 312,883 | -7% | -$931,160 | |||||
| M | 2026-01-13 | SRZN | Surrozen, Inc./De | Kutzkey Tim | Dir, 10% | P - Purchase | $19.86 | +17,993 | 2,229,270 | +1% | +$357,353 | |||||
| M | 2026-01-13 | SRZN | Surrozen, Inc./De | Column Group III Gp, LP | 10% | P - Purchase | $19.86 | +17,993 | 2,229,270 | +1% | +$357,353 | |||||
2026-01-12 | ATRA | Atara Biotherapeutics, Inc. | Panacea Innovation Ltd | 10% | S - Sale | $6.07 | -80,554 | 1,373,182 | -6% | -$489,019 | ||||||
| M | 2026-01-12 | DVLT | Datavault Ai Inc. | Scilex Holding Co | 10% | S - Sale | $0.83 | -15,965,541 | 213,766,229 | -7% | -$13,215,896 | |||||
| D | 2026-01-12 | ADPT | Adaptive Biotechnologies Corp | Lo Francis | Chief People Officer | S - Sale+OE | $17.73 | -79,590 | 318,478 | -20% | -$1,411,131 | |||||
2026-01-14 | ACLX | Arcellx, Inc. | Heery Christopher | CHIEF MEDICAL OFFICER | S - Sale | $68.51 | -5,882 | 23,749 | -20% | -$402,997 | ||||||
| D | 2026-01-12 | ADPT | Adaptive Biotechnologies Corp | Piskel Kyle | CFO | S - Sale+OE | $18.00 | -4,290 | 216,637 | -2% | -$77,220 | |||||
| D | 2026-01-12 | TSHA | Taysha Gene Therapies, Inc. | Nagendran Sukumar | Pres, Head of R, D | S - Sale+OE | $4.71 | -200,000 | 1,433,439 | -12% | -$942,000 | |||||
2026-01-09 | PALI | Palisade Bio, Inc. | Williams Donald Allen | Dir | P - Purchase | $1.88 | +5,000 | 8,728 | +134% | +$9,400 | ||||||
2026-01-13 | ACLX | Arcellx, Inc. | Heery Christopher | CHIEF MEDICAL OFFICER | S - Sale | $65.51 | -7,437 | 29,631 | -20% | -$487,213 | ||||||
| D | 2026-01-13 | SLDB | Solid Biosciences Inc. | Tan Kevin | CFO, Treasurer | S - Sale+OE | $5.27 | -5,704 | 46,100 | -11% | -$30,060 | |||||
| D | 2026-01-09 | CGON | Cg Oncology, Inc. | Mulay James | Dir | S - Sale+OE | $52.47 | -11,145 | 0 | -100% | -$584,799 | |||||
2026-01-09 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $35.26 | -2,738 | 140,031 | -2% | -$96,545 | ||||||
2026-01-12 | ACLX | Arcellx, Inc. | Heery Christopher | CHIEF MEDICAL OFFICER | S - Sale | $64.15 | -6,131 | 37,068 | -14% | -$393,286 | ||||||
2026-01-08 | ABOS | Acumen Pharmaceuticals, Inc. | Zuga Matt | CFO, Chief Business Officer | S - Sale | $1.82 | -6,888 | 209,951 | -3% | -$12,513 | ||||||
2026-01-08 | ABOS | Acumen Pharmaceuticals, Inc. | Barton Russell | COO | S - Sale | $1.86 | -3,530 | 123,269 | -3% | -$6,562 | ||||||
| M | 2026-01-08 | ABOS | Acumen Pharmaceuticals, Inc. | Meisner Derek M | GC, Corp Sec | S - Sale | $1.80 | -50,659 | 83,800 | -38% | -$91,073 | |||||
| M | 2026-01-08 | ABOS | Acumen Pharmaceuticals, Inc. | Oconnell Daniel Joseph | CEO | S - Sale | $1.77 | -26,472 | 593,510 | -4% | -$46,954 | |||||
2026-01-09 | FATE | Fate Therapeutics Inc | Tahl Cindy | See Remarks | S - Sale | $1.06 | -10,589 | 387,081 | -3% | -$11,275 | ||||||
| D | 2026-01-08 | PASG | Passage Bio, Inc. | Chou William | Pres, CEO | S - Sale+OE | $18.44 | -4,076 | 6,524 | -38% | -$75,159 | |||||
2026-01-09 | FATE | Fate Therapeutics Inc | Valamehr Bahram | Pres, CEO | S - Sale | $1.07 | -5,190 | 329,708 | -2% | -$5,557 | ||||||
| D | 2026-01-08 | PASG | Passage Bio, Inc. | Borthwick Kathleen | CFO | S - Sale+OE | $18.44 | -2,062 | 5,402 | -28% | -$38,022 | |||||
| D | 2026-01-07 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale+OE | $77.84 | -18,700 | 212,523 | -8% | -$1,455,613 | |||||
| D | 2026-01-07 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Pres, R, D, CMO | S - Sale+OE | $40.20 | -25,156 | 0 | -100% | -$1,011,299 | |||||
| M | 2026-01-07 | ABOS | Acumen Pharmaceuticals, Inc. | Doherty James J. | Pres, CDO | S - Sale | $1.85 | -8,167 | 54,033 | -13% | -$15,148 | |||||
2026-01-07 | ABOS | Acumen Pharmaceuticals, Inc. | Schacterle Amy | Chief Regulatory Officer | S - Sale | $1.98 | -1,097 | 7,703 | -12% | -$2,176 | ||||||
| D | 2026-01-07 | RVMD | Revolution Medicines, Inc. | Horn Margaret A | COO | S - Sale+OE | $100.56 | -75,000 | 141,053 | -35% | -$7,542,023 | |||||
| D | 2026-01-07 | RVMD | Revolution Medicines, Inc. | Anders Jack | CFO | S - Sale+OE | $98.00 | -10,000 | 108,065 | -8% | -$980,000 | |||||
| D | 2026-01-07 | VCEL | Vericel Corp | Halpin Michael | COO | S - Sale+OE | $40.48 | -10,000 | 16,080 | -38% | -$404,800 | |||||
2026-01-07 | GLUE | Monte Rosa Therapeutics, Inc. | Warmuth Markus | Pres, CEO | S - Sale | $23.49 | -5,466 | 618,937 | -1% | -$128,373 | ||||||
2026-01-07 | IMVT | Immunovant, Inc. | Stout Jay S | CTO | S - Sale | $26.53 | -1,203 | 199,611 | -1% | -$31,914 | ||||||
2026-01-06 | ADPT | Adaptive Biotechnologies Corp | Robins Harlan S | Chief Scientific Officer | S - Sale | $16.44 | -10,000 | 1,222,312 | -1% | -$164,400 | ||||||
| M | 2026-01-06 | DVLT | Datavault Ai Inc. | Scilex Holding Co | 10% | S - Sale | $1.24 | -14,713,490 | 229,731,770 | -6% | -$18,176,455 | |||||
| D | 2026-01-06 | CRSP | Crispr Therapeutics AG | Prasad Raju | CFO | S - Sale+OE | $60.16 | -29,700 | 6,767 | -81% | -$1,786,636 | |||||
2026-01-06 | SRZN | Surrozen, Inc./De | Column Group III Gp, LP | 10% | P - Purchase | $19.89 | +15,100 | 2,211,277 | +1% | +$300,297 | ||||||
2026-01-06 | SRZN | Surrozen, Inc./De | Kutzkey Tim | Dir, 10% | P - Purchase | $19.89 | +15,100 | 2,211,277 | +1% | +$300,297 | ||||||
2026-01-06 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $4.36 | -220,000 | 6,649,863 | -3% | -$959,200 | ||||||
| DM | 2026-01-06 | MAZE | Maze Therapeutics, Inc. | Sohn Catherine A. | Dir | S - Sale+OE | $39.07 | -29,413 | 0 | -100% | -$1,149,054 | |||||
2026-01-06 | DNLI | Denali Therapeutics Inc. | Watts Ryan J. | Pres, CEO | S - Sale | $16.50 | -35,198 | 2,449,437 | -1% | -$580,767 | ||||||
2026-01-06 | DNLI | Denali Therapeutics Inc. | Schuth Alexander O. | COFO, Secretary | S - Sale | $16.50 | -17,218 | 806,577 | -2% | -$284,097 | ||||||
| M | 2026-01-05 | ABOS | Acumen Pharmaceuticals, Inc. | Zuga Matt | CFO, Chief Business Officer | S - Sale | $1.97 | -14,905 | 216,839 | -6% | -$29,436 | |||||
| M | 2026-01-05 | ABOS | Acumen Pharmaceuticals, Inc. | Siemers Eric | Chief Medical Officer | S - Sale | $1.96 | -10,834 | 159,464 | -6% | -$21,277 | |||||
| M | 2026-01-05 | ABOS | Acumen Pharmaceuticals, Inc. | Oconnell Daniel Joseph | CEO | S - Sale | $1.98 | -47,506 | 619,982 | -7% | -$94,176 | |||||
| M | 2026-01-05 | ABOS | Acumen Pharmaceuticals, Inc. | Meisner Derek M | GC, Corp Sec | S - Sale | $1.98 | -26,668 | 134,459 | -17% | -$52,690 | |||||
| M | 2026-01-05 | ABOS | Acumen Pharmaceuticals, Inc. | Barton Russell | COO | S - Sale | $1.97 | -9,318 | 126,799 | -7% | -$18,325 | |||||
| AD | 2025-12-22 | ADPT | Adaptive Biotechnologies Corp | Lo Francis | Chief People Officer | S - Sale+OE | $17.50 | -4,394 | 318,478 | -1% | -$76,895 | |||||
2026-01-05 | ADPT | Adaptive Biotechnologies Corp | Robins Chad M | CEO, COB | S - Sale | $15.59 | -124,998 | 2,584,243 | -5% | -$1,948,719 | ||||||
| M | 2017-03-31 | CDTX | Cidara Therapeutics, Inc. | Stein Jeffrey | Pres, CEO | P - Purchase | $79.55 | +4,262 | 75,640 | +6% | +$339,040 | |||||
| M | 2026-01-05 | PMCB | Pharmacyte Biotech, Inc. | Silverman Joshua | CEO, Pres | P - Purchase | $0.80 | +100,000 | 466,250 | +27% | +$80,476 | |||||
| M | 2026-01-05 | PMCB | Pharmacyte Biotech, Inc. | Schechter Jonathan | Dir | P - Purchase | $0.80 | +60,000 | 192,500 | +45% | +$48,232 | |||||
| D | 2026-01-05 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | Dir | S - Sale+OE | $4.25 | -40,000 | 913,839 | -4% | -$170,000 | |||||
2026-01-06 | RLAY | Relay Therapeutics, Inc. | Patel Sanjiv | Pres, CEO | S - Sale | $7.82 | -43,168 | 1,547,944 | -3% | -$337,574 | ||||||
| D | 2026-01-05 | SRZN | Surrozen, Inc./De | Li Yang | Exec. VP, Research | S - Sale+OE | $19.87 | -1,118 | 16,793 | -6% | -$22,209 | |||||
| D | 2026-01-05 | SRZN | Surrozen, Inc./De | Williams Charles O | COO | S - Sale+OE | $19.87 | -1,566 | 12,982 | -11% | -$31,109 | |||||
| DM | 2026-01-02 | APGE | Apogee Therapeutics, Inc. | Henderson Jane | CFO | S - Sale+OE | $76.14 | -8,000 | 185,371 | -4% | -$609,146 | |||||
| D | 2026-01-02 | ADPT | Adaptive Biotechnologies Corp | Lo Francis | Chief People Officer | S - Sale+OE | $16.08 | -3,125 | 318,478 | -1% | -$50,250 | |||||
2026-01-05 | HALO | Halozyme Therapeutics, Inc. | Connaughton Bernadette | Dir | S - Sale | $70.25 | -2,000 | 40,123 | -5% | -$140,500 | ||||||
| D | 2026-01-05 | SLDB | Solid Biosciences Inc. | Ganot Ilan | Dir | S - Sale+OE | $5.43 | -1,053 | 132,085 | -1% | -$5,718 | |||||
| DM | 2026-01-02 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Pres, R, D, CMO | S - Sale+OE | $40.39 | -4,844 | 0 | -100% | -$195,668 | |||||
| D | 2026-01-02 | MAZE | Maze Therapeutics, Inc. | Bachrodt Amy | SVP, Finance | S - Sale+OE | $39.15 | -5,000 | 12,965 | -28% | -$195,754 | |||||
2026-01-02 | TARS | Tarsus Pharmaceuticals, Inc. | Whitfield Dianne C. | CHRO | S - Sale | $80.67 | -15,565 | 23,393 | -40% | -$1,255,684 | ||||||
| D | 2026-01-02 | ATHA | Athira Pharma, Inc. | San Martin Javier | CHIEF MEDICAL OFFICER | S - Sale+OE | $6.88 | -1,644 | 10,189 | -14% | -$11,311 | |||||
| D | 2026-01-02 | ATHA | Athira Pharma, Inc. | Litton Mark James | Pres, CEO | S - Sale+OE | $6.88 | -2,586 | 42,796 | -6% | -$17,792 | |||||
| D | 2026-01-02 | ATHA | Athira Pharma, Inc. | Renninger Robert | CFO | S - Sale+OE | $6.88 | -297 | 12,857 | -2% | -$2,043 | |||||
| D | 2026-01-02 | ATHA | Athira Pharma, Inc. | Church Kevin | Chief Scientific Officer | S - Sale+OE | $6.88 | -876 | 20,681 | -4% | -$6,027 | |||||
| D | 2026-01-02 | ATHA | Athira Pharma, Inc. | Worthington Mark | GC, CCO | S - Sale+OE | $6.88 | -876 | 13,978 | -6% | -$6,027 | |||||
2025-12-31 | BEAM | Beam Therapeutics Inc. | Emany Sravan Kumar | CFO | S - Sale | $27.10 | -6,294 | 73,706 | -8% | -$170,567 | ||||||
2025-12-31 | BEAM | Beam Therapeutics Inc. | Bellon Christine | GC | S - Sale | $27.10 | -1,254 | 115,667 | -1% | -$33,983 | ||||||
| D | 2026-01-05 | GLUE | Monte Rosa Therapeutics, Inc. | Nickson Philip | Chief Business, Legal Officer | S - Sale+OE | $15.17 | -3,155 | 60,845 | -5% | -$47,861 | |||||
| D | 2026-01-05 | GLUE | Monte Rosa Therapeutics, Inc. | Champoux Jennifer | COO | S - Sale+OE | $15.17 | -2,629 | 62,371 | -4% | -$39,882 | |||||
| D | 2026-01-02 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | Dir | S - Sale+OE | $7.60 | -10,312 | 88,020 | -10% | -$78,371 | |||||
2026-01-05 | GLUE | Monte Rosa Therapeutics, Inc. | Dunn Edmund | Principal Accounting Officer | S - Sale | $15.17 | -1,039 | 22,693 | -4% | -$15,762 | ||||||
| D | 2026-01-05 | GLUE | Monte Rosa Therapeutics, Inc. | Warmuth Markus | Pres, CEO | S - Sale+OE | $15.17 | -10,135 | 624,403 | -2% | -$153,748 | |||||
| D | 2026-01-05 | GLUE | Monte Rosa Therapeutics, Inc. | Janku Filip | Chief Medical Officer | S - Sale+OE | $15.17 | -3,155 | 75,026 | -4% | -$47,861 | |||||
| D | 2026-01-05 | GLUE | Monte Rosa Therapeutics, Inc. | Townson Sharon | Chief Scientific Officer | S - Sale+OE | $15.17 | -3,155 | 67,845 | -4% | -$47,861 | |||||
2026-01-02 | VIR | Vir Biotechnology, Inc. | Sato Vicki L | Dir | S - Sale | $5.93 | -22,000 | 1,166,391 | -2% | -$130,383 | ||||||
2025-12-31 | PCVX | Vaxcyte, Inc. | Dhaliwal Harpreet S. | Chief Technical Ops Officer | S - Sale | $46.69 | -9,743 | 23,928 | -29% | -$454,891 | ||||||
| D | 2025-12-31 | KYMR | Kymera Therapeutics, Inc. | Mainolfi Nello | CEO | S - Sale+OE | $78.06 | -30,000 | 663,077 | -4% | -$2,341,939 | |||||
| DM | 2025-12-29 | MAZE | Maze Therapeutics, Inc. | Dandekar Atul | CSBO | S - Sale+OE | $40.56 | -72,500 | 10,503 | -87% | -$2,940,799 | |||||
| D | 2025-12-29 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Pres, R, D, CMO | S - Sale+OE | $40.56 | -45,000 | 0 | -100% | -$1,825,355 | |||||
| DM | 2025-12-29 | MAZE | Maze Therapeutics, Inc. | Bachrodt Amy | SVP, Finance | S - Sale+OE | $40.41 | -15,000 | 12,965 | -54% | -$606,173 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |